The story of psychedelics as therapeutic treatments is now unfolding across the world. There is a lot of promising research into a wide variety of problematic neurological and psychological conditions that have resisted more traditional treatments to date. It’s a potentially explosive industry in its infancy. “Psychedelics are a boom business.”
Recreational: $ 8-19.2B calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $ 373B + calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
M2Bio Sciences, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands.
In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.
M2Bio Sciences, Inc. is currently in Pre-enrolment Patient- screening for Phase 1 Human trial.
Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases. With its recent acquisition of Psilocin Pharma Corp., Revive will advance Psilocybin-based therapeutics in various diseases and disorders and will prioritize development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.
Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison to Evaluate Novel Formulations and Drug Delivery Technology Focused on Psilocybin-Based Pharmaceuticals.
The Company is also exploring the use of Bucillamine for the potential treatment of infectious diseases, including COVID-19.
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.
COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.
Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering. The company’s immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. In addition, the company has established a microdosing division to conduct clinical trials of LSD microdosing for adult ADHD. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines.
Mind Cure is focused on finding new ways to treat the profound distress of a world suffering from a mental health crisis. This is a tremendous opportunity to bring a new category of psychoactive and psychedelic treatments to market.
Mind Cure’s founding team and advisors have deep and industry-specific experience in bio tech, life sciences, new product discovery, research, technology and entrepreneurship.
The Company is uniquely situated in Canada, benefiting from a sophisticated investment community, a world-class educated scientific professionals and Government leadership in research; where Health Canada demonstrates that a science-first approach will pave the pathway for innovative research.
Field Trip is leading the medical and scientific re-emergence of psychedelics and psychedelic-enhanced therapies. Through Field Trip Health’s intentionally-designed, technology-empowered clinics providing psychedelic therapies, Field Trip Digital’s apps and resources scaling our protocols globally, and Field Trip Discovery.
Our drug development division developing the next generation of psychedelic molecules, we help people through an integrated, evidence-based approach to healing and thriving.
Red Light Holland’s business revolves around the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal, recreational market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.
Red Light Holland is strategically based in the Netherlands, an area with a long-standing, established legal magic truffles market.
Numinus is at the forefront of addressing the growing prevalence of mental health issues and desire for greater wellness. Through Numinus Bioscience (in alignment with licence holder Salvation Botanicals Ltd), Numinus has a dealer’s licence which allows the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. Numinus is seeking to expand the licence to include activities such as import/export, testing and R&D. The expanded licence will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances.
Numinus also operates a stand-alone centre offering patients integrative health solutions. A purpose-built facility is planned for Vancouver in 2021.
Champignon Brands Inc. is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes for patients suffering with conditions like depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders.
Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified.
ATAI Life Sciences
Tassili Life Sciences, Corp